NCT07457775 2026-03-09
Liposomal Irinotecan in Combination With Temozolomide and Bevacizumab in Patients With Advanced STS
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Not yet recruiting
Clinical Trials
10 trialsNCT04200443 2026-01-05
Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma
City of Hope Medical Center
Phase 2 Active not recruiting
NCT03709680 2025-01-14
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
Pfizer
Phase 2 Active not recruiting
NCT02511132 2022-12-22
A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma
Gradalis, Inc.
Phase 2 Completed
NCT01055314 2017-08-29
Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00881595 2017-02-10
SA02
University of Florida
Phase 2 Withdrawn
NCT00003273 2015-12-03
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
NYU Langone Health
Phase 2 Withdrawn
NCT00003718 2014-01-06
Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00033709 2014-01-06
Temozolomide and Thalidomide in Treating Patients With Metastatic, Locally Advanced, or Unresectable Leiomyosarcoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00194766 2007-11-14
Continuous Temozolomide in Patients With Advanced or Metastatic Soft Tissue Sarcoma or Metastatic Breast Cancer
University of Washington
Phase 2 Completed